Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 311Nivolumab 159Carboplatin 158Cisplatin 140Cyclophosphamide 135Paclitaxel 129Magnetic Resonance Spectroscopy 99Specimen Handling 96Radiotherapy 93Gemcitabine 88Dexamethasone 86Biopsy 81Ipilimumab 81Docetaxel 78Doxorubicin 77Rituximab 71Etoposide 69durvalumab 62Lenalidomide 61Radiation 61atezolizumab 60Prednisone 59Pemetrexed 58Taxes 58Bevacizumab 55fludarabine 54olaparib 53Vincristine 52Cytarabine 51Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × tagraxofusp × 1 year × Clear all
NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡